These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18676821)

  • 1. The Arf/p53 pathway in cancer and aging.
    Matheu A; Maraver A; Serrano M
    Cancer Res; 2008 Aug; 68(15):6031-4. PubMed ID: 18676821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed ageing through damage protection by the Arf/p53 pathway.
    Matheu A; Maraver A; Klatt P; Flores I; Garcia-Cao I; Borras C; Flores JM; Viña J; Blasco MA; Serrano M
    Nature; 2007 Jul; 448(7151):375-9. PubMed ID: 17637672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53-Dependent and -independent functions of the Arf tumor suppressor.
    Sherr CJ; Bertwistle D; DEN Besten W; Kuo ML; Sugimoto M; Tago K; Williams RT; Zindy F; Roussel MF
    Cold Spring Harb Symp Quant Biol; 2005; 70():129-37. PubMed ID: 16869746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-aging activity of the Ink4/Arf locus.
    Matheu A; Maraver A; Collado M; Garcia-Cao I; Cañamero M; Borras C; Flores JM; Klatt P; Viña J; Serrano M
    Aging Cell; 2009 Apr; 8(2):152-61. PubMed ID: 19239418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ink4a/Arf links senescence and aging.
    Sharpless NE
    Exp Gerontol; 2004; 39(11-12):1751-9. PubMed ID: 15582292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer biology: can less be more for p53?
    Berns A
    Nature; 2006 Sep; 443(7108):153-4. PubMed ID: 16971934
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased Arf/p53 activity in stem cells, aging and cancer.
    Carrasco-Garcia E; Moreno M; Moreno-Cugnon L; Matheu A
    Aging Cell; 2017 Apr; 16(2):219-225. PubMed ID: 28101907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulation of INK4/ARF in cancer and aging.
    Kim WY; Sharpless NE
    Cell; 2006 Oct; 127(2):265-75. PubMed ID: 17055429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression.
    Christophorou MA; Ringshausen I; Finch AJ; Swigart LB; Evan GI
    Nature; 2006 Sep; 443(7108):214-7. PubMed ID: 16957739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?
    Soussi T; Hjortsberg L
    Trends Mol Med; 2009 Jan; 15(1):1-4. PubMed ID: 19097939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 Deficiency leads to compensatory up-regulation of p16INK4a.
    Leong WF; Chau JF; Li B
    Mol Cancer Res; 2009 Mar; 7(3):354-60. PubMed ID: 19240179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small mitochondrial ARF (smARF) is located in both the nucleus and cytoplasm, induces cell death, and activates p53 in mouse fibroblasts.
    Ueda Y; Koya T; Yoneda-Kato N; Kato JY
    FEBS Lett; 2008 Apr; 582(10):1459-64. PubMed ID: 18381074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the tumor suppressor ARF in oncogenesis].
    Pimkina IuS; Dorosevich AE
    Arkh Patol; 2009; 71(1):60-3. PubMed ID: 19514363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A conditional mouse model for malignant mesothelioma.
    Jongsma J; van Montfort E; Vooijs M; Zevenhoven J; Krimpenfort P; van der Valk M; van de Vijver M; Berns A
    Cancer Cell; 2008 Mar; 13(3):261-71. PubMed ID: 18328429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.
    Cheng K; Grisendi S; Clohessy JG; Majid S; Bernardi R; Sportoletti P; Pandolfi PP
    Oncogene; 2007 Nov; 26(53):7391-400. PubMed ID: 17546053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype-rescue of cyclin-dependent kinase inhibitor p16/INK4A defects in a spontaneous canine cell model of breast cancer.
    DeInnocentes P; Agarwal P; Bird RC
    J Cell Biochem; 2009 Feb; 106(3):491-505. PubMed ID: 19130492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TRIP from ULF to ARF.
    Collado M; Serrano M
    Cancer Cell; 2010 Apr; 17(4):317-8. PubMed ID: 20385357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [P53, ARF and P16: the last defence against reprogrammation].
    Dijon-Grinand M; De Vos J
    Med Sci (Paris); 2009 Oct; 25(10):793-4. PubMed ID: 19849977
    [No Abstract]   [Full Text] [Related]  

  • 19. Deregulated expression of p16INK4a and p53 pathway members in benign and malignant myoepithelial tumours of the salivary glands.
    Vékony H; Röser K; Löning T; Raaphorst FM; Leemans CR; Van der Waal I; Bloemena E
    Histopathology; 2008 Dec; 53(6):658-66. PubMed ID: 19076682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors.
    Zhang S; Tang Q; Xu F; Xue Y; Zhen Z; Deng Y; Liu M; Chen J; Liu S; Qiu M; Liao Z; Li Z; Luo D; Shi F; Zheng Y; Bi F
    Mol Cancer Res; 2009 Apr; 7(4):570-80. PubMed ID: 19372585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.